BIO-Europe Spring EBD Group BIO BIO-Europe Spring
Share:
Email this page Share this on LinkedIn Share this on Twitter

BIO-Europe Spring® 2015 Press Releases

News for BIO-Europe Spring® 2015 will be available soon

BIO-Europe Spring 2014 press releases

March 20, 2014BIO-Europe Spring® 2014 partnering event brought over 2,000 life science executives to Turin, Italy last week The eighth annual BIO-Europe Spring® international partnering conference took place last week, March 10–12 in Turin, Italy. The event, held at the Oval Lingotto conference center, welcomed more than 2,000 participants representing over 1,200 companies from 42 countries vying for 2,115 licensing opportunities. More than 10,700 one-to-one meetings took place at the event b...  more ►

March 3, 2014BIO-Europe Spring® 2014 kicks off next week in Turin, ItalyEvent is gathering of life science industry leaders
The eighth annual BIO-Europe Spring® conference kicks off in one week on March 10–12 in Turin, Italy. The event is expected to draw over 2,000 high-level executives from pharma, biotech, venture capital firms, and service companies who will be coming to Turin to engage in one-to-one partnering meetings with innovative biotech startups. Delegates are expected to engage in...  more ►

February 25, 2014"Competition fierce" as big pharma moves to early stage deals The focus for Roche meetings at BIO-Europe Spring® breaks out roughly with a third devoted to ongoing relationships, another third focused on active negotiation and one third opportunistic. "We have to spend more time filtering through that last third, but I can tell you we have found programs over the past year that quickly moved to a high priority status."
more ►

February 12, 2014BIO-Europe Spring® program in Turin will engage executives in provocative topics facing drug development industry Life science executives are quickly filling up the program at the eighth annual BIO-Europe Spring® conference to be held March 10–12, 2014 in Turin, Italy. The international bio-pharma partnering event annually attracts top international executives from established and emerging biotech companies; pharmaceutical companies; private investors including venture capital and priva...  more ►

join the conversation ►

January 29, 2014Spotlight on Turin Business Facts A BUSINESS HUB: According to 2012 data provided by the Register of Enterprises, held by the Torino Chamber of Commerce, the number of businesses based in the Torino Province equals 237,000. LIFE SCIENCES: The Turin Life Science sector comprises medium and large companies operating in the following fields: Medical, Electromedical, and Diagnostic instrumentation; Orthopedic pros...  more ►

join the conversation ►

December 12, 2013Turin, Italy welcomes the 2014 edition of BIO-Europe Spring®Pharmaceutical dealmakers converge upon Italian innovation hub
The eighth annual BIO-Europe Spring® conference will be held March 10–12, 2014 in Turin, Italy at the OVAL Lingotto conference center. The event is recognized by life science insiders as the place for established biotech and early-stage companies to meet and form partnerships with venture capitalists and business development executives from big pharma companies. Investor...  more ►

join the conversation ►


partnering360® Blog

September 16, 2014 Innovation at Sanofi Sanofi looks for innovation in it’s drug portfolio in a variety of places – from the acquisitions they’ve made in their business to partnerships with venture capital, biotech and Pharma.  In a recent article at Insight, Gary J. Nabel, Senior VP, CSO and deputy to the President for... more ►

September 11, 2014 New therapeutic development models build researchers’ commercialization savvy Guest post from David Altman, Technology & Innovation Development Office, Boston Children’s Hospital Academic researchers and physician innovators are great at making research discoveries and developing inventions at an early stage. But if you were to fund them to turn their research... more ►

September 10, 2014 Broad Institute: Focus on cardiac arrhythmia Later this month at the BioPharm America™,  institutions from around the world will join us to present their latest innovations and discoveries. Today, we take a look at the Broad Institute and one of their latest innovative studies. Scientists came together to study heart arrhythmias and how... more ►

September 5, 2014 Building a Better Partnering Presentation Excerpts from “Building a Better Partnering Presentation” paper by Linda Pullan, PhD, of Pullan Consulting are republished here by permission from ShareVault® Whether seeking a partnership with another company to obtain funds, or looking to advance a drug candidate or technology, organizations... more ►

September 4, 2014 Due diligence: How to ensure a successful process It is largely accepted that the biggest challenges for life science companies in completing M&A or partnering deals are regulatory compliance and financial due diligence issues. The quality of due diligence can be a key influencer on success. For a biotech, identifying issues early, and opening... more ►



partnering360:Insight Latest headlines from partnering360:Insight

September 9, 2014 Flagship Ventures explores the pharma innovation supply chain The care and feeding of the innovation supply chain is a primary focus for Flagship Ventures. While other venture capital firms are focusing on new financing options, this venture firm takes the more holistic approach of fostering innovation among early, disruptive platform companies—many of which they’ve created from scratch in-house—and forging relationships with larger firms that can take the platforms all the way to commercialization. more ►

September 5, 2014 Sanofi finds innovation in many places With ten therapeutic areas plus animal health, Sanofi’s R&D portfolio is well balanced to build upon the strengths of each of the franchises in its portfolio and to capitalize on innovative ideas and projects outside the company. more ►

August 13, 2014 Gene, stem cell therapies bring new players to partnering The next generation of therapies built upon the science of stem cells and genetics will require new types of partnerships. If there is promise that these technologies can redefine how we understand and treat disease, there is already a certainty that the alliances and partnerships required to bring these therapies to patients are also beyond traditional models for commercialization. more ►

August 1, 2014 J&J: “Innovation delivers growth and growth sustains our innovation” "What we are really trying to accomplish is building more than a financial relationship. We are interested in truly finding a way to get to the outcomes. We want to keep our partners intimately involved in a pursuit of truth, in understanding what this science means in the lives of patients who might benefit the most from it. It is this dialogue we are after." more ►

July 28, 2014 Deal trends in Regenerative Medicine The field of regenerative medicine is an up-and-coming new approach for targeting and treating diseases, involving the repair and restoration of previously damaged tissues or organs in the body. According to the Current Agreements life science deals and alliance database, there have been over 700 regenerative medicine/stem cell deals in the last five years alone. more ►



Arrow Up


 
 
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2014 EBD GmbH
Privacy Policy
Terms of Use
BIO-Europe Spring EBD Group BIO BIO-Europe Spring